Hoth Therapeutics (HOTH) has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs, providing the company with exclusive rights to a jointly owned patent portfolio co-developed by the the U.S. Department of Veterans Affairs and Emory University. The licensed technology centers on Glial Cell Line-Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions. Hoth Therapeutics will have exclusive rights to develop, market, and commercialize products and processes derived from the licensed patents.
Hoth has also entered into an agreement to protect its intellectual property by signing an LOI to acquire additional provisional patent protection for its therapeutic HT-001.
Shares of Hoth Therapeutics are up 9% in pre-market trade on Thursday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.